San Antonio, TXNCT04617522Now EnrollingIRB Ready

Advanced or Metastatic Solid Tumor Clinical Trial in San Antonio, TX

Access cutting-edge advanced or metastatic solid tumor treatment through this clinical trial at a research site in San Antonio. Study-provided care at no cost to qualified participants.

Sponsored by Gilead Sciences

Quick Self-Assessment

See if you qualify for this San Antonio location

Preparing your pre-screening questions…

Expert Care in San Antonio

Access advanced or metastatic solid tumor specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related advanced or metastatic solid tumor treatment provided free

Apply for This San Antonio Location

Check if you qualify for this advanced or metastatic solid tumor clinical trial in San Antonio, TX

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to San Antonio

    Convenient for TX residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit San Antonio site if eligible
  4. 4Begin participation

About This Advanced or Metastatic Solid Tumor Study in San Antonio

The goals of this clinical study are to learn more about the safety and dosing of the study drug, sacituzumab govitecan-hziy, in participants with solid tumors and moderate liver problems.

Sponsor: Gilead Sciences

Who Can Participate

Inclusion Criteria

for all Individuals:
Histologically confirmed advanced or metastatic solid tumor that is measurable or nonmeasurable.
Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2.
Adequate hematologic counts without transfusional or growth factor support within 2 weeks of study drug initiation (hemoglobin ≥ 9 g/dL, absolute neutrophil count (ANC) ≥1,500/mm\^3, and platelets ≥ 100,000/ μL).
Creatinine clearance ≥ 30 mL/min as assessed by the Cockcroft-Gault equation. Key Inclusion Criteria for Individuals with Normal Hepatic Function:
Normal hepatic function (total bilirubin ≤ ULN and aspartate aminotransferase (AST) ≤ 3.0× ULN). Key Inclusion Criteria for Individuals with Moderate Hepatic Function:
Moderate hepatic impairment (1.5 × ULN \< total bilirubin ≤ 3.0 × ULN and any level of AST).
For individuals with hepatic encephalopathy, the condition does not, in the Investigator's opinion, interfere with the individual's ability to provide an appropriate informed consent. Key

Exclusion Criteria

for all Individuals:
Have poor venous access.
Donated or lost 500mL or more of blood volume (including plasmapheresis) to plans to donate during the study.
Have had a prior anticancer biologic agent within 4 weeks prior to Day 1 or have had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to Day 1 and who have not recovered (i.e., ≤ Grade 1) from adverse events (AEs) at the time of study entry. Individuals participating in observational studies are eligible.
Had prior treatment with irinotecan within 4 weeks prior to Day 1.
Have not recovered (i.e., ≤ Grade 1) from AEs due to a previously administered agent.
Have an active second malignancy.
Have known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Individuals with previously treated brain metastases may participate provided they have stable CNS disease for at least 4 weeks prior to the first dose of study drug and all neurologic symptoms have returned to baseline, have no evidence of new or enlarging brain metastases, and are taking \< 20 mg/day of prednisone or its equivalent. All individuals with carcinomatous meningitis are excluded regardless of clinical stability.
Have history of cardiac disease.
Have active chronic inflammatory bowel disease (ulcerative colitis or Crohn's disease) or gastrointestinal (GI) perforation within 6 months of enrollment.
Have active serious infection (Contact medical monitor for clarification).
High-dose systemic corticosteroids (≥20 mg of prednisone or its equivalent) are not allowed within 2 weeks of Check-In. However, inhaled, intranasal, intra-articular, and topical steroids are allowed.
Use of strong inhibitor or inducer of UGT1A1.
Have a known history of Gilbert's disease. Key Exclusion Criteria for Individuals with Normal Hepatic Impairment:
Must have pre-existing condition interfering with hepatic and/or renal function that could interfere with the metabolism and/or excretion of the study drug. Key Exclusion Criteria for Individuals with Moderate Hepatic Impairment:
Had a significant clinical exacerbation of liver disease symptoms within the 2-week period before administration of study drug (i.e., abdominal pain, nausea, vomiting, anorexia, or fever).
Had clinically demonstrable, tense ascites.
Had evidence of acute viral hepatitis within 1 month prior to administration of study drug.
Have evidence of hepatorenal syndrome.
Individuals with transjugular intrahepatic portosystemic shunt (TIPS) placement.
Have active Stage 3 or 4 encephalopathy.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in San Antonio?

Yes, this clinical trial (NCT04617522) has an active research site in San Antonio, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Advanced or Metastatic Solid Tumor Treatment Options in San Antonio, TX

If you're searching for advanced or metastatic solid tumor treatment options in San Antonio, TX, this clinical trial (NCT04617522) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our San Antonio research site is actively enrolling participants for this clinical trial. You'll receive care from experienced advanced or metastatic solid tumor specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all advanced or metastatic solid tumor clinical trials near you to find additional studies recruiting in your area.

More Advanced Solid Tumors Trials in San Antonio, TX

See all advanced solid tumors clinical trials recruiting in San Antonio — not just this study.

Browse Advanced Solid Tumors Trials in San Antonio →

Browse More Trials by Condition

Advanced Solid Tumors TrialsAlzheimers Disease TrialsEssential Tremor TrialsAnkylosing Spondylitis TrialsAtopic Dermatitis TrialsErectile Dysfunction TrialsInterstitial Cystitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in San Antonio?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · San Antonio, TX